MolDx Program
Foundation Medicine, Natera Launch ctDNA Therapy Response Assay With Medicare Coverage
The tissue-informed ctDNA assay is available to US physicians and is eligible for coverage through both the MolDx and New York's CLEP programs.
NeoGenomics Gets Medicare Coverage for Radar Minimal Residual Disease Assay in Breast Cancer
The firm's tumor-informed, patient-personalized tests are now covered for residual disease detection and monitoring in breast cancer patients effective March 24.
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.
Qlucore Raises SEK 30M as it Looks Toward IPO
The Swedish bioinformatics firm sees its greatest growth potential in precision cancer diagnostics as it prepares to go public in the next 12 months.